These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36599002)

  • 1. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.
    Birch SM; Lawlor MW; Conlon TJ; Guo LJ; Crudele JM; Hawkins EC; Nghiem PP; Ahn M; Meng H; Beatka MJ; Fickau BA; Prieto JC; Styner MA; Struharik MJ; Shanks C; Brown KJ; Golebiowski D; Bettis AK; Balog-Alvarez CJ; Clement N; Coleman KE; Corti M; Pan X; Hauschka SD; Gonzalez JP; Morris CA; Schneider JS; Duan D; Chamberlain JS; Byrne BJ; Kornegay JN
    Sci Transl Med; 2023 Jan; 15(677):eabo1815. PubMed ID: 36599002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
    Le Guiner C; Servais L; Montus M; Larcher T; Fraysse B; Moullec S; Allais M; François V; Dutilleul M; Malerba A; Koo T; Thibaut JL; Matot B; Devaux M; Le Duff J; Deschamps JY; Barthelemy I; Blot S; Testault I; Wahbi K; Ederhy S; Martin S; Veron P; Georger C; Athanasopoulos T; Masurier C; Mingozzi F; Carlier P; Gjata B; Hogrel JY; Adjali O; Mavilio F; Voit T; Moullier P; Dickson G
    Nat Commun; 2017 Jul; 8():16105. PubMed ID: 28742067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.
    Shin JH; Pan X; Hakim CH; Yang HT; Yue Y; Zhang K; Terjung RL; Duan D
    Mol Ther; 2013 Apr; 21(4):750-7. PubMed ID: 23319056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
    Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
    J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The golden retriever model of Duchenne muscular dystrophy.
    Kornegay JN
    Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.
    Kornegay JN; Li J; Bogan JR; Bogan DJ; Chen C; Zheng H; Wang B; Qiao C; Howard JF; Xiao X
    Mol Ther; 2010 Aug; 18(8):1501-8. PubMed ID: 20517298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.
    Martin PT; Zygmunt DA; Ashbrook A; Hamilton S; Packer D; Birch SM; Bettis AK; Balog-Alvarez CJ; Guo LJ; Nghiem PP; Kornegay JN
    PLoS One; 2021; 16(3):e0248721. PubMed ID: 33770101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.
    Yue Y; Pan X; Hakim CH; Kodippili K; Zhang K; Shin JH; Yang HT; McDonald T; Duan D
    Hum Mol Genet; 2015 Oct; 24(20):5880-90. PubMed ID: 26264580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward Gene Therapy for Duchenne Muscular Dystrophy.
    Chamberlain JR; Chamberlain JS
    Mol Ther; 2017 May; 25(5):1125-1131. PubMed ID: 28416280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.
    Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D
    Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
    Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.
    Martin PT; Golden B; Okerblom J; Camboni M; Chandrasekharan K; Xu R; Varki A; Flanigan KM; Kornegay JN
    PLoS One; 2014; 9(2):e88226. PubMed ID: 24505439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.
    Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Li J; Nghiem P; Detwiler DA; Larsen CA; Grange RW; Bhavaraju-Sanka RK; Tou S; Keene BP; Howard JF; Wang J; Fan Z; Schatzberg SJ; Styner MA; Flanigan KM; Xiao X; Hoffman EP
    Mamm Genome; 2012 Feb; 23(1-2):85-108. PubMed ID: 22218699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
    Athanasopoulos T; Foster H; Foster K; Dickson G
    Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdystrophin Gene Addition Significantly Improves Muscle Functionality and Diaphragm Muscle Histopathology in a Fibrotic Mouse Model of Duchenne Muscular Dystrophy.
    Cernisova V; Lu-Nguyen N; Trundle J; Herath S; Malerba A; Popplewell L
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.